ORMP Insider Trading Activity and SEC Form 4 Filings
ORMP insider trading summary
Over the past 12 months, insiders at Oramed Pharmaceuticals Inc. (ORMP) reported 4 sales worth $1.2M by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $1.2M.
Latest ORMP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Avraham Gabay | Chief Financial Officer | Sell | $90K (20,000 @ $4.51) |
| Oct 1, 2026 | Joshua Hexter | COO & Cbo | Sell | $135K (30,000 @ $4.51) |
| Jul 1, 2026 | Joshua Hexter | COO & Cbo | Sell | $611K (137,000 @ $4.46) |
| Jul 1, 2026 | Avraham Gabay | Chief Financial Officer | Sell | $331K (73,360 @ $4.51) |
| Apr 4, 2023 | Arie Mayer | Director | Buy | $8K (3,800 @ $2.21) |
| Apr 3, 2023 | Arie Mayer | Director | Buy | $11K (5,009 @ $2.22) |
| Mar 16, 2023 | Nadav Kidron | President and CEO | Buy | $53K (26,000 @ $2.04) |
| Mar 14, 2023 | Nadav Kidron | President and CEO | Buy | $201K (100,000 @ $2.01) |
| Mar 14, 2023 | Miriam Kidron | Chief Scientific Officer | Sell | $201K (100,000 @ $2.01) |
| Mar 14, 2023 | Yadin Rozov | Director | Buy | $102K (50,000 @ $2.05) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.